Dolutegravir (DTG) was approved for treating HIV in adults and adolescents in 2013. In 2018, the Tsepamo Study reported a significantly increased neural tube defect (NTD) risk in women conceiving on DTG (0.94%), leading to a safety alert. In July 2019, additional data showed NTD prevalence with periconception DTG to be lower than in the initial analysis, but still greater than seen for other antiretroviral exposures (0.3% vs 0.1%). We aimed to assess birth outcomes following prenatal DTG use using real-world data
Dolomite-EPPICC is a multi-cohort European observational study of DTG use in pregnant women living with HIV and their infants. Analysis of prospectively collected individual patient data on all pregnancies with any prenatal DTG exposure and with birth outcomes reported by Feb 2019 was conducted. Periconception exposure was defined as being within the first 6 weeks of gestation (WG).
A total of 453 pregnancies in 428 women from 6 cohorts were included. Women were mainly of black African (229, 54%) and white (129, 30%) ethnicity. Most (326/428, 76%) women had heterosexual HIV acquisition, 42 women were vertically infected and 11 had injecting drug use history. Of 443 singleton pregnancies, 16 were terminated (1 for birth defects at 29WG for neuronal migration disorder and severe microcephaly, with periconception DTG exposure) and 22 ended in spontaneous abortion; of 10 twin pregnancies, 1 was terminated and in 1, a fetus miscarried. There were 417 live-born infants (229 male, 185 female, 3 missing), born at median 39WG (IQR 38, 40). Five infants were stillborn, all exposed to periconception DTG, none with birth defects. The Table shows birth outcomes for the 400 live-born singleton infants (no twins had birth defects); 266 (67%) had periconception DTG exposure. One neonate died at 2 days (born at 23 GW) with periconception DTG exposure. Among the 417 live-born infants there were 17 with reported birth defects (4.1%, 95% CI 2.4, 6.5); 1 infant had 2 defects. The 18 defects were in the following systems: genitourinary (7), heart (3), limb addition (polydactyly, 3), gastrointestinal (2), other (3); no CNS defects were reported. There were no vertical transmissions (106 infants still indeterminate)
The birth defect rate and pattern add further support to current evidence on safety of periconception DTG use. This study is ongoing, in order to provide robust pharmacovigilance data in Europe.